{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03132922",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ADP-0044-001"
      },
      "Organization": {
        "OrgFullName": "Adaptimmune",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "MAGE-A4ᶜ¹º³²T for Multi-Tumor",
      "OfficialTitle": "Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 5, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2032",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2035",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 25, 2017",
      "StudyFirstSubmitQCDate": "April 25, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 28, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 4, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 5, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Adaptimmune",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Urinary Bladder Cancer",
          "Melanoma",
          "Head and Neck Cancer",
          "Ovarian Cancer",
          "Non-Small Cell Lung Cancer",
          "Esophageal Cancer",
          "Gastric Cancer",
          "Synovial Sarcoma",
          "Myxoid Round Cell Liposarcoma",
          "Gastroesophageal Junction"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Cell Therapy",
          "T Cell Therapy",
          "SPEAR T Cell",
          "MAGE-A4",
          "Immuno-oncology",
          "Metastatic",
          "Urothelial Cancer",
          "Previously Treated",
          "T Cell Receptor",
          "Squamous, adenosquamous, adenocarcinoma or large cell NSCLC",
          "Squamous or adenocarcinoma esophageal cancer",
          "Sarcoma",
          "Melanoma",
          "Bladder",
          "Ovarian",
          "Radiation therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "52",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Genetic: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Radiation Sub-Study: Autologous genetically modified MAGE-A4c1",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Radiation: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Genetic",
            "InterventionName": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells",
            "InterventionDescription": "Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells"
              ]
            }
          },
          {
            "InterventionType": "Radiation",
            "InterventionName": "Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation",
            "InterventionDescription": "Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Radiation Sub-Study: Autologous genetically modified MAGE-A4c1"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of subjects with adverse events (AE), including serious adverse events (SAEs).",
            "PrimaryOutcomeDescription": "Determine if treatment with autologous genetically modified T cells (MAGE-A4ᶜ¹º³²T) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation.",
            "PrimaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "PrimaryOutcomeMeasure": "Determining dose limiting toxicities (DLT) and optimally tolerated dose range",
            "PrimaryOutcomeDescription": "Evaluate DLTs and toxicity assessment using NCI CTCAE.",
            "PrimaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "PrimaryOutcomeMeasure": "Evaluation of persistence of genetically modified T cells.",
            "PrimaryOutcomeDescription": "Evaluation of persistence of genetically modified T cells in the periphery.",
            "PrimaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "PrimaryOutcomeMeasure": "Measurement of RCL in genetically modified T cells.",
            "PrimaryOutcomeDescription": "Evaluation of RCL in subject PBMCs using PCR-based assay.",
            "PrimaryOutcomeTimeFrame": "3.5 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of time to first response.",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of duration of response.",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Interval between the date of first documented evidence of stable disease (SD) until first documented disease progression or death due to any cause.",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of duration of stable disease.",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Interval between the date of first T cell infusion and the earliest date of disease, progression or death due to any cause",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of progression-free survival.",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Interval between the date of first T cell infusion and date of death due to any cause.",
            "SecondaryOutcomeDescription": "Evaluation of the efficacy of the treatment by assessment of overall survival.",
            "SecondaryOutcomeTimeFrame": "3.5 years"
          },
          {
            "SecondaryOutcomeMeasure": "Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)",
            "SecondaryOutcomeDescription": "New occurrence of any malignancy\nNew occurrence or exacerbation of a pre-existing neurologic disorder\nNew occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder\nNew occurrence of a hematologic disorder\nNew occurrence of any opportunistic and/or serious infections\nNew occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy",
            "SecondaryOutcomeTimeFrame": "15 years post last treatment (infusion)"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "MAGE-A4c1032T cell trafficking in tumor lesion(s).",
            "OtherOutcomeDescription": "Evaluation of post-infusion T-cell trafficking in irradiated vs non-irradiation lesions",
            "OtherOutcomeTimeFrame": "3.5 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubject is ≥18 years of age at the time of signing the study informed consent.\nSubject has histologically confirmed diagnosis of any one of the indicated tumor types\nSubject is HLA-A*02 positive. (This determination will be made under screening protocol ADP-0000-001).\nSubject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination will be made under screening protocol ADP-0000-001).\nAdequate organ function as indicated in the study protocol\nSubject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion\nSubject meets disease-specific requirements per protocol\n\n7. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.\n\nExclusion Criteria:\n\nSubject does not express appropriate HLA-A genotype\nSubject is receiving excluded therapy/treatment per protocol\nSubject has symptomatic CNS metastases.\nSubject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.\nSubject has active infection with HIV, HBV, HCV or HTLV\nSubject is pregnant or breastfeeding.\n\nAdditional Exclusion Criteria for the Radiation Substudy:\n\nSubject does not meet eligibility criteria for the main study (ADP-0044-001).\nSubject does not have at least one target lesion amenable to radiation.\nCertain radiation therapy within 6 months of clinical trial are an exclusion.\nMetastatic disease impinging on the spinal cord or threatening spinal cord compression.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "David Hong, MD",
            "OverallOfficialAffiliation": "M.D. Anderson Cancer Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Miami",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Moffitt Cancer Center",
            "LocationCity": "Tampa",
            "LocationState": "Florida",
            "LocationZip": "33612",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Washington University School of Medicine",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63110",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Washington University",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63112",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Roswell Park Cancer Institute",
            "LocationCity": "Buffalo",
            "LocationState": "New York",
            "LocationZip": "14263",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Duke University Medical Center, Duke Cancer Institute",
            "LocationCity": "Durham",
            "LocationState": "North Carolina",
            "LocationZip": "27710",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Ohio State University Wexner Medical Center",
            "LocationCity": "Columbus",
            "LocationState": "Ohio",
            "LocationZip": "43210",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Fox Chase Cancer Center",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19111",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Tennessee Oncology - Sarah Cannon Research Institute",
            "LocationCity": "Nashville",
            "LocationState": "Tennessee",
            "LocationZip": "37203",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "M.D. Anderson Cancer Center",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Princess Margaret Cancer Centre",
            "LocationCity": "Toronto",
            "LocationState": "Ontario",
            "LocationZip": "M5G1X6",
            "LocationCountry": "Canada"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32002290",
            "ReferenceType": "derived",
            "ReferenceCitation": "Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008545",
            "ConditionMeshTerm": "Melanoma"
          },
          {
            "ConditionMeshId": "D000012509",
            "ConditionMeshTerm": "Sarcoma"
          },
          {
            "ConditionMeshId": "D000001749",
            "ConditionMeshTerm": "Urinary Bladder Neoplasms"
          },
          {
            "ConditionMeshId": "D000004938",
            "ConditionMeshTerm": "Esophageal Neoplasms"
          },
          {
            "ConditionMeshId": "D000008080",
            "ConditionMeshTerm": "Liposarcoma"
          },
          {
            "ConditionMeshId": "D000013584",
            "ConditionMeshTerm": "Sarcoma, Synovial"
          },
          {
            "ConditionMeshId": "D000018208",
            "ConditionMeshTerm": "Liposarcoma, Myxoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000018358",
            "ConditionAncestorTerm": "Neuroendocrine Tumors"
          },
          {
            "ConditionAncestorId": "D000017599",
            "ConditionAncestorTerm": "Neuroectodermal Tumors"
          },
          {
            "ConditionAncestorId": "D000009373",
            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009380",
            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
          },
          {
            "ConditionAncestorId": "D000018326",
            "ConditionAncestorTerm": "Nevi and Melanomas"
          },
          {
            "ConditionAncestorId": "D000018204",
            "ConditionAncestorTerm": "Neoplasms, Connective and Soft Tissue"
          },
          {
            "ConditionAncestorId": "D000014565",
            "ConditionAncestorTerm": "Urogenital Neoplasms"
          },
          {
            "ConditionAncestorId": "D000005770",
            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
          },
          {
            "ConditionAncestorId": "D000004067",
            "ConditionAncestorTerm": "Digestive System Neoplasms"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000005767",
            "ConditionAncestorTerm": "Gastrointestinal Diseases"
          },
          {
            "ConditionAncestorId": "D000006258",
            "ConditionAncestorTerm": "Head and Neck Neoplasms"
          },
          {
            "ConditionAncestorId": "D000014571",
            "ConditionAncestorTerm": "Urologic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000001745",
            "ConditionAncestorTerm": "Urinary Bladder Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000004935",
            "ConditionAncestorTerm": "Esophageal Diseases"
          },
          {
            "ConditionAncestorId": "D000018205",
            "ConditionAncestorTerm": "Neoplasms, Adipose Tissue"
          },
          {
            "ConditionAncestorId": "D000009372",
            "ConditionAncestorTerm": "Neoplasms, Connective Tissue"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M1704",
            "ConditionBrowseLeafName": "Carcinoma, Ovarian Epithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10324",
            "ConditionBrowseLeafName": "Lung Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4698",
            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2737",
            "ConditionBrowseLeafName": "Adenocarcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12126",
            "ConditionBrowseLeafName": "Ovarian Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10680",
            "ConditionBrowseLeafName": "Melanoma",
            "ConditionBrowseLeafAsFound": "Melanoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7240",
            "ConditionBrowseLeafName": "Esophageal Neoplasms",
            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14479",
            "ConditionBrowseLeafName": "Sarcoma",
            "ConditionBrowseLeafAsFound": "Sarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15216",
            "ConditionBrowseLeafName": "Stomach Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8500",
            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4182",
            "ConditionBrowseLeafName": "Urinary Bladder Neoplasms",
            "ConditionBrowseLeafAsFound": "Urinary Bladder Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10232",
            "ConditionBrowseLeafName": "Liposarcoma",
            "ConditionBrowseLeafAsFound": "Liposarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15513",
            "ConditionBrowseLeafName": "Sarcoma, Synovial",
            "ConditionBrowseLeafAsFound": "Synovial Sarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19506",
            "ConditionBrowseLeafName": "Liposarcoma, Myxoid",
            "ConditionBrowseLeafAsFound": "Round Cell Liposarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19648",
            "ConditionBrowseLeafName": "Neuroendocrine Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18997",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19540",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11470",
            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11477",
            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11598",
            "ConditionBrowseLeafName": "Nevus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11600",
            "ConditionBrowseLeafName": "Nevus, Pigmented",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19623",
            "ConditionBrowseLeafName": "Nevi and Melanomas",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19502",
            "ConditionBrowseLeafName": "Neoplasms, Connective and Soft Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16467",
            "ConditionBrowseLeafName": "Urogenital Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8038",
            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6408",
            "ConditionBrowseLeafName": "Digestive System Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16472",
            "ConditionBrowseLeafName": "Urologic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4178",
            "ConditionBrowseLeafName": "Urinary Bladder Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7237",
            "ConditionBrowseLeafName": "Esophageal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19503",
            "ConditionBrowseLeafName": "Neoplasms, Adipose Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11469",
            "ConditionBrowseLeafName": "Neoplasms, Connective Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4352",
            "ConditionBrowseLeafName": "Ovarian Cancer",
            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4354",
            "ConditionBrowseLeafName": "Ovarian Epithelial Cancer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2141",
            "ConditionBrowseLeafName": "Esophageal Cancer",
            "ConditionBrowseLeafAsFound": "Esophageal Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T5486",
            "ConditionBrowseLeafName": "Stomach Cancer",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5284",
            "ConditionBrowseLeafName": "Soft Tissue Sarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3479",
            "ConditionBrowseLeafName": "Liposarcoma",
            "ConditionBrowseLeafAsFound": "Liposarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T5553",
            "ConditionBrowseLeafName": "Synovial Sarcoma",
            "ConditionBrowseLeafAsFound": "Synovial Sarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4027",
            "ConditionBrowseLeafName": "Myxoid Liposarcoma",
            "ConditionBrowseLeafAsFound": "Round Cell Liposarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4091",
            "ConditionBrowseLeafName": "Neuroendocrine Tumor",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4092",
            "ConditionBrowseLeafName": "Neuroepithelioma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}